Postpartum Depression

Neurology
3
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
2 programs
1
SAGE-217 15/20 mg Oral SolutionPhase 31 trial
ZuranoloneN/A1 trial
Active Trials
NCT07398469Recruiting200Est. Mar 2027
NCT02978326Completed276Est. Dec 2018
GH Research
GH ResearchDUBLIN 2, Ireland
1 program
1
GH001Phase 21 trial
Active Trials
NCT05804708TerminatedEst. Nov 2024
Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
1
BRII-297Phase 11 trial
Active Trials
NCT05845840CompletedEst. Jan 2024
Alliance Pharmaceuticals
1 program
Leuprolide AcetateN/A2 trials
Active Trials
NCT04455750Active Not Recruiting61Est. Sep 2027
NCT01762943Completed36Est. Oct 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsLeuprolide Acetate
BiogenSAGE-217 15/20 mg Oral Solution
GH ResearchGH001
Brii BiosciencesBRII-297
BiogenZuranolone
Alliance PharmaceuticalsLeuprolide Acetate

Clinical Trials (6)

Total enrollment: 573 patients across 6 trials

NCT04455750Alliance PharmaceuticalsLeuprolide Acetate

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Start: Oct 2021Est. completion: Sep 202761 patients
Phase 3Active Not Recruiting
NCT02978326BiogenSAGE-217 15/20 mg Oral Solution

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Start: Jan 2017Est. completion: Dec 2018276 patients
Phase 3Completed
NCT05804708GH ResearchGH001

Phase 2 Clinical Trial of GH001 in Postpartum Depression

Start: Mar 2023Est. completion: Nov 2024
Phase 2Terminated
NCT05845840Brii BiosciencesBRII-297

A Study of BRII-297 in Healthy Adult Subjects

Start: May 2023Est. completion: Jan 2024
Phase 1Completed
NCT07398469BiogenZuranolone

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

Start: Dec 2025Est. completion: Mar 2027200 patients
N/ARecruiting
NCT01762943Alliance PharmaceuticalsLeuprolide Acetate

Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition

Start: Aug 2013Est. completion: Oct 201636 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 573 patients
4 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)